Acino Holding AG (LTS:0QM8) Total Equity: CHF334.16 Mil (As of Dec. 2013)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Acino Holding AG Total Equity?

Acino Holding AG LTS:0QM8 Total Equity is CHF334.16 Mil as of Dec. 2013.

Acino Holding AG's total equity for the quarter that ended in Dec. 2013 was CHF334.16 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Acino Holding AG Total Equity Historical Data

* Premium members only.

The historical data trend for Acino Holding AG's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acino Holding AG Total Equity Chart

Acino Holding AG Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 384.44 323.72 316.14 337.89 334.16

Acino Holding AG Semi-Annual Data
Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 384.44 323.72 316.14 337.89 334.16

Acino Holding AG Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Acino Holding AG's Total Equity for the fiscal year that ended in Dec. 2013 is calculated as

Total Equity=Total Assets(Q: Dec. 2013 )-Total Liabilities(Q: Dec. 2013 )
=560.516-226.359
=334.16

Acino Holding AG's Total Equity for the quarter that ended in Dec. 2013 is calculated as

Total Equity=Total Assets(Q: Dec. 2013 )-Total Liabilities(Q: Dec. 2013 )
=560.516-226.359
=334.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of CHF334.16 Mil mean?
Acino Holding AG (LTS:0QM8) has a Total Equity of CHF334.16 Mil as of Dec. 2013. The total amount of equity as record on a company's balance sheet. View historical data for Acino Holding AG and its competitors.
Is Acino Holding AG's Total Equity too high?
Acino Holding AG's current Total Equity is CHF334.16 Mil.
How does Acino Holding AG's Total Equity compare to competitors?
Acino Holding AG's Total Equity of CHF334.16 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Acino Holding AG and its competitors. Acino Holding AG's current Total Equity is CHF334.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acino Holding AG stock overvalued right now?
Acino Holding AG (LTS:0QM8) has a current Total Equity of CHF334.16 Mil. The current Total Equity is CHF334.16 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Acino Holding AG (LTS:0QM8), the current Total Equity is CHF334.16 Mil as of Dec. 2013. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Acino Holding AG Business Description

Acino Holding AG is a Switzerland-based company engaged in the pharmaceutical industry. The Company develops, manufactures, and markets pharmaceuticals in novel drug delivery forms internationally. It is divided into four segments Business to Consumer (BtC); Business to Business (BtB); Technology marketing (TM); and Production (Prod). The BtC segment comprises all direct marketing activities. Under the company's "Acino Switzerland" brand and, with the promise of Swiss quality, the company sells its products in emerging markets around the globe. This reporting segment includes the business purchased from Mepha/Cephalon in the Middle East, Africa, Latin America and Asia. The BtB segment comprises Acino's business with its internally developed products, for which the company also owns the intellectual property rights. Acino develops and produces high-quality medicines with proven active ingredients and modern drug delivery systems and grants licenses for them to leading pharmaceutical and generic pharmaceutical companies worldwide. The technology marketing segment comprises a broad spectrum of fully integrated contract services, including procurement, contract development, production and packaging for companies in the life sciences industry. On behalf of these customers, Acino develops a comprehensive product pipeline on the basis of its special technological know-how. This includes both new types of medicines as well as projects with innovative drug delivery systems for established active ingredients. The production segment is responsible for the manufacturing of products and the supplying of the other three segments, and generates turnover through the reimbursement of its services. The manufacturing costs of products are credited to the production segment at standard prices along with remuneration in the form of a mark-up for materials and production costs.